ArticleCureus2025
Diagnostic and Therapeutic Challenges in Concurrent Addison's Disease and Acromegaly.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The simultaneous occurrence of Addison's disease and acromegaly presents a unique and complex clinical challenge. Addison's disease, characterized by autoimmune adrenal destruction, results in cortisol and aldosterone deficiencies, while acromegaly stems from excessive growth hormone secretion, usually due to a pituitary adenoma. Their coexistence complicates diagnosis and management due to overlapping systemic effects. We report a 53-year-old woman initially diagnosed with Addison's disease, presenting with fatigue, hypotension, and hyperpigmentation. Four years later, she developed acromegalic symptoms, including acral enlargement and hyperhidrosis. Laboratory assessments confirmed elevated insulin-like growth factor-1 (IGF-1) and growth hormone levels, with imaging revealing two pituitary microadenomas. The patient underwent transsphenoidal surgery, achieving tumor debulking and hormonal stabilization. Addison's disease management involved hydrocortisone, fludrocortisone, and levothyroxine, complicated by metabolic instability and hypertension. Additional comorbidities included diabetes, glaucoma, and sleep apnea, necessitating a multidisciplinary approach. Long-term follow-up demonstrated stable IGF-1 levels and no recurrence. This case illustrates the rare co-occurrence of Addison's disease and acromegaly, highlighting diagnostic delays, difficulties in endocrine management, and the critical importance of structured long-term follow-up. Special attention is paid to the impact of incomplete mineralocorticoid evaluation, missed opportunities for early diabetes screening, and evolving pituitary insufficiency after tumor resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.